HaWPYC is an international Post-Market Clinical Follow-up (PMCF) to collect post-market safety and performance data on commercially available Pyrocarbon (PyC) hand and wrist implants used in this study. Data may be used for Post-Market Surveillance, and regulatory requirements.

The objective of this multicenter study is to collect preoperative, intraoperative, intermediate (approx. 2 years), mid-term (approx. 5 years), and long-term (approx. 10 years) postoperative data, on related clinical complications and clinical outcomes on the Sponsors market-approved hand and wrist Pyrocarbon implants, to demonstrate safety and performance of these implants in a real-world setting.

Inclusion Criteria:

• 18 years or older at the time he/she receives the information and signs the informed consent (when applicable as per local regulatory requirements),

• Informed on the study and willing to sign an informed consent form approved by Institutional Review Board or Ethics Committee,

• Willing and able to comply with the requirements of the study protocol,

• For prospective inclusion: considered for treatment with one of PyC Hand/Wrist study implants (primary or revision surgery),

• For "ambispective" inclusion: must have undergone a Hand or Wrist arthroplasty with a PyC Hand/Wrist study implant before the date of first site initiation visit,

  • Follow-up visits (at least the last two) must be prospective,
  • Patient must have complete information available for each completed visit

Exclusion Criteria:

• Patient pertaining to one of the categories referred to as "vulnerable population" in the French Law (articles L. 1121-5 to L. 1121-8 of the French Public Health Code), or as "particularly vulnerable persons" in the Swiss Federal Law (Chapter 3, Sections 1 to 4 of CC 810.30 Federal Act on Research involving Human Beings - Human Research Act, HRA),
• Patient unable to comply with the study procedures based on the judgment of the investigator (e.g. cannot comprehend study questions, inability to keep scheduled assessment times),
• Any medical condition that could impact on the study outcomes functional signification at the investigator's discretion (e.g., neuropathy, allergy…)

417 patients will be enrolled (About 50 to 80 per implant type). Prospective patients: screening and surgery should occur after the First site initiation visit.

"Ambispective" patients:

• Screening and surgery occurred before the date of the first site initiation visit,
• Follow-up visits (at least the last two) must be prospective (i.e: must occur after the date of the first site initiation visit),
• Inclusions of consecutive patients,
• Minimum available data must be available for each completed visit.